Patents by Inventor Paul Barstad

Paul Barstad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7208156
    Abstract: Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: April 24, 2007
    Assignee: La Jolla Pharmaceutical Company
    Inventors: Paul A. Barstad, G. Michael Iverson
  • Patent number: 7163683
    Abstract: Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: January 16, 2007
    Assignee: La Jolla Pharmaceutical Company
    Inventors: Paul A. Barstad, G. Michael Iverson
  • Patent number: 7138244
    Abstract: Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: November 21, 2006
    Assignee: La Jolla Pharmaceutical Company
    Inventors: Paul A. Barstad, Gilbert M. Iverson
  • Patent number: 7138250
    Abstract: The present invention provides a method of determining thiopurine methyltransferase (TPMT) activity in a subject. The method includes the steps of reacting sample obtained from the subject with a thiopurine derivative that is not 6-mercaptopurine to produce a methylated purine product; contacting the reacted sample with acid, thereby precipitating proteinaceous material from the reacted sample; separating supernatant from the precipitated proteinaceous material; and detecting in the supernatant the methylated purine product, where the amount of the methylated purine product indicates a level of thiopurine methyltransferase activity in the subject. In a method of the invention, the subject can be, for example, an inflammatory bowel disease patient. In one embodiment, the acid used to precipitate proteinaceous material is perchloric acid, for example, 70% perchloric acid. In another embodiment, the thiopurine derivative used as a substrate is 6-thioguanine.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: November 21, 2006
    Assignee: Prometheus Laboratories, Inc.
    Inventor: Paul Barstad
  • Publication number: 20050170436
    Abstract: Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.
    Type: Application
    Filed: October 1, 2004
    Publication date: August 4, 2005
    Inventors: Paul Barstad, Gilbert Iverson
  • Publication number: 20050031635
    Abstract: Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.
    Type: Application
    Filed: July 16, 2004
    Publication date: February 10, 2005
    Inventors: Stephen Coutts, Paul Barstad, G. Iverson, David Jones
  • Publication number: 20030199015
    Abstract: The present invention provides a method of determining thiopurine methyltransferase (TPMT) activity in a subject. The method includes the steps of reacting sample obtained from the subject with a thiopurine derivative that is not 6-mercaptopurine to produce a methylated purine product; contacting the reacted sample with acid, thereby precipitating proteinaceous material from the reacted sample; separating supernatant from the precipitated proteinaceous material; and detecting in the supernatant the methylated purine product, where the amount of the:methylated purine product indicates a level of thiopurine methyltransferase activity in the subject. In a method of the invention, the subject can be, for example, an inflammatory bowel disease patient. In one embodiment, the acid used to precipitate proteinaceous material is perchloric acid, for example, 70% perchloric acid. In another embodiment, the thiopurine derivative used as a substrate is 6-thioguanine.
    Type: Application
    Filed: May 2, 2003
    Publication date: October 23, 2003
    Inventor: Paul Barstad
  • Patent number: 6576438
    Abstract: The present invention provides a method of determining thiopurine methyltransferase (TPMT) activity in a subject. The method includes the steps of reacting sample obtained from the subject with a thiopurine derivative that is not 6-mercaptopurine to produce a methylated purine product; contacting the reacted sample with acid, thereby precipitating proteinaceous material from the reacted sample; separating supernatant from the precipitated proteinaceous material; and detecting in the supernatant the methylated purine product, where the amount of the methylated purine product indicates a level of thiopurine methyltransferase activity in the subject. In a method of the invention, the subject can be, for example, an inflammatory bowel disease patient. In one embodiment, the acid used to precipitate proteinaceous material is perchloric acid, for example, 70% perchloric acid. In another embodiment, the thiopurine derivative used as a substrate is 6-thioguanine.
    Type: Grant
    Filed: May 16, 2001
    Date of Patent: June 10, 2003
    Assignee: Prometheus Laboratories, Inc.
    Inventor: Paul Barstad
  • Publication number: 20030103990
    Abstract: Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.
    Type: Application
    Filed: February 20, 2002
    Publication date: June 5, 2003
    Inventors: Stephen M. Coutts, Paul A. Barstad, G. Michael Iverson, David S. Jones
  • Publication number: 20020028476
    Abstract: The present invention provides a method of determining thiopurine methyltransferase (TPMT) activity in a subject. The method includes the steps of reacting sample obtained from the subject with a thiopurine derivative that is not 6-mercaptopurine to produce a methylated purine product; contacting the reacted sample with acid, thereby precipitating proteinaceous material from the reacted sample; separating supernatant from the precipitated proteinaceous material; and detecting in the supernatant the methylated purine product, where the amount of the methylated purine product indicates a level of thiopurine methyltransferase activity in the subject. In a method of the invention, the subject can be, for example, an inflammatory bowel disease patient. In one embodiment, the acid used to precipitate proteinaceous material is perchloric acid, for example, 70% perchloric acid. In another embodiment, the thiopurine derivative used as a substrate is 6-thioguanine.
    Type: Application
    Filed: May 16, 2001
    Publication date: March 7, 2002
    Inventor: Paul Barstad
  • Patent number: 6060056
    Abstract: Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.
    Type: Grant
    Filed: September 8, 1993
    Date of Patent: May 9, 2000
    Assignee: La Jolla Pharmaceutical Company
    Inventors: Stephen M. Coutts, Paul A. Barstad, G. Michael Iverson, David S. Jones
  • Patent number: 5268454
    Abstract: Conjugates of stable nonimmunogenic polymers and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.
    Type: Grant
    Filed: February 8, 1991
    Date of Patent: December 7, 1993
    Assignee: La Jolla Pharmaceutical Company
    Inventors: Paul A. Barstad, Gilbert M. Iverson
  • Patent number: 4962023
    Abstract: An immunoassay method for one-step detection of specific antibodies which includes incubation of a solid phase support or matrix having a spot of the antigen bound thereto with a sample of the clinical fluid to be tested in the presence of a signal developing reagent, including a detector substance, which is preferably a colloidal metal sol, and a ligand, such as protein A or other antibody binding ligand. A diagnostic field kit containing the test antigens and signal developing reagent is also described.
    Type: Grant
    Filed: June 22, 1987
    Date of Patent: October 9, 1990
    Assignee: Louisiana State University, Agricultural and Mechanical College
    Inventors: William J. Todd, Paul A. Barstad
  • Patent number: 4425438
    Abstract: A method and device for assaying a test substance utilizing a primary absorbent substance for selectively allowing only a quantity of an analytical reagent proportional to the quantity of test substance to pass therethrough when test substance and analytical reagent are contacted with the primary absorbent. An analytical absorbent is disposed in a series of zones for sequentially absorbing the analytical reagent which passes through the primary absorbent so that detection of the last zone of absorbed analytical reagent indicates the quantity of test substance. The method comprises passing test substance and analytical reagent through the primary absorbent and then the analytical absorbent followed by detection of the last zone in which analytical reagent is absorbed. The device comprises a funnel with the primary absorbent therein for directing the test substance and analytical reagent to a narrow tube holding the analytical absorbent.
    Type: Grant
    Filed: March 13, 1981
    Date of Patent: January 10, 1984
    Inventors: David S. Bauman, Paul A. Barstad